Navigation Links
Boston Scientific Announces Results for Third Quarter Ended September 30, 2007
Date:10/19/2007

NATICK, Mass., Oct. 19 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for the third quarter ended September 30, 2007, as well as guidance for net sales and earnings per share (EPS) for the fourth quarter of 2007.

Highlights

- Reported net sales of $2.048 billion, which was at the mid-point of

guidance, and adjusted EPS of $0.20, which exceeded guidance

- Attained number one position in the worldwide drug-eluting stent (DES)

market

- Achieved DES market share leadership in Japan

- Reached 56 percent market share in the U.S. DES market, up from

54 percent last quarter

- Reported year-over-year worldwide cardiac rhythm management (CRM) sales

growth of 16 percent, including implantable cardioverter defibrillator

(ICD) growth of 18 percent

- Announced several new initiatives designed to increase shareholder

value, including the planned sale of business units, and expense and

head count reductions

- Amended the Company's term loan agreement, providing increased

financial flexibility, while prepaying $1 billion of the loan

Net sales for the third quarter of 2007 were $2.048 billion as compared to $2.026 billion for the third quarter of 2006. Worldwide sales of the Company's drug-eluting coronary stent systems for the third quarter of 2007 were $448 million as compared to $572 million for the third quarter of 2006. U.S. sales of drug-eluting coronary stent systems for the third quarter of 2007 were $240 million as compared to $384 million for the third quarter of 2006. International sales of drug-eluting coronary stent systems were $208 milli 44 (180)

Income (loss) before income taxes 27 (3,704)

Income taxes 64 150

Net loss $(37) $(3,854)

Net loss per common share - assuming

dilution $(0.02) $(3.19)

Weighted average shares outstanding -

assuming dilution 1,485.5 1,207.0

BOSTON SCIENTIFIC CORPORATION

NON-GAAP NET INCOME (LOSS) AND NET INCOME (LOSS)

PER COMMON SHARE RECONCILIATIONS

(Unaudited)

NOTE - An explanation of the ways in which Boston Scientific management uses these non-GAAP measures to evaluate its business, the substance behind Boston Scientific management's decision to use these non-GAAP measures, the material limitations associated with the use of these non-GAAP measures, the manner in which Boston Scientific management compensates for those limitations, and the substantive reasons why Boston Scientific management believes that these non-GAAP measures provide useful information to investors is included in the exhibit labeled "Use of Non-GAAP Financial Measures."

Nine Months Ended Nine Months Ended

September 30, September 30,

2007 2006

Impact Impact

Net per Net per

income diluted income diluted

(loss) share (loss) share

In millions, except per share data

GAAP results $(37) $(0.02) $(3,854) $(3.19)

Non-GAAP adjustments:

Acquisition and divestiture

related charges 456 0.30 4,566 3.77

Amortization expense 383 0.25 (1) 256 0.21 (2)

Adjusted results $802 $0.53 (1) $968 $0.79 (2)

(1) Calculated by assuming stock-based dilution of 14.5 million shares

(2) Calculated by assuming stock based dilution of 14.3 million shares

Nine Months Ended

September 30,

2007 2006

Acquisition and divestiture related

charges

Loss on assets held for sale $352

Purchased research and development 72 $4,184

Integration costs (a) 34 42

Fair-value adjustment for the sharing

of proceeds feature of the Abbott

Laboratories stock purchase (b) 8 100

Step-up value of inventory sold (c) 279

CRM technology offering charge (c) 31

Charitable donation (b) 5

AAA program cancellation net credit (d) (13)

466 4,628

Income tax benefit (e) (10) (62)

Acquisition and divestiture related

charges, net of tax $456 $4,566

Amortization expense:

Amortization expense $467 $333

Income tax benefit (e) (84) (77)

Amortization expense, net of tax $383 $256

(a) Recorded $25 million in 2007 to selling, general and administrative

expenses, $6 million to cost of products sold and $3 million to

research and development expenses; recorded $39 million in 2006 to

selling, general and administrative expenses, and $3 million to

research and development expenses.

(b) Recorded to other, net.

(c) Recorded to cost of products sold.

(d) Recorded a credit of $67 million to purchased research and

development, a charge of $31 million to research and development

expenses and a charge of $23 million to amortization expense.

(e) Amounts are tax effected at the Company's anticipated effective tax

rate, unless the amount is a significant unusual or infrequently

occurring item in accordance with FASB Interpretation No. 18,

"Accounting for Income Taxes in Interim Periods".

BOSTON SCIENTIFIC CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

September 30, December 31,

In millions 2007 2006

Assets

Current assets:

Cash and cash equivalents $1,237 $1,668

Trade accounts receivable, net 1,511 1,424

Inventories 836 749

Deferred income taxes 637 583

Other current assets 317 477

Total current assets 4,538 4,901

Property, plant and equipment, net 1,775 1,726

Investments 435 596

Other assets 177 237

Intangible assets, net 24,409 23,636

$31,334 $31,096

Liabilities and Stockholders' Equity

Current liabilities:

Borrowings due within one year $254 $7

Accounts payable and accrued expenses 2,624 2,067

Other current liabilities 459 556

Total current liabilities 3,337 2,630

Long-term debt 7,903 8,895

Deferred income taxes 2,463 2,784

Other long-term liabilities 2,114 1,489

Stockholders' equity 15,517 15,298

$31,334 $31,096

BOSTON SCIENTIFIC CORPORATION

WORLDWIDE SALES

(Unaudited)

Three Months Ended

September 30, Change

As

Reported Constant

Currency Currency

In millions 2007 2006 Basis Basis

DOMESTIC $1,207 $1,273 (5%) (5%)

Europe 418 400 4% (3%)

Asia Pacific 311 239 30% 29%

Inter-Continental 112 114 (1%) (7%)

INTERNATIONAL 841 753 12% 7%

WORLDWIDE $2,048 $2,026 1% (1%)

Three Months Ended

September 30, Change

As

Reported Constant

Currency Currency

In millions 2007 2006 Basis Basis

Interventional

Cardiology $762 $868 (12%) (13%)

Peripheral Interventions/

Vascular Surgery 154 154 0% (3%)

Electrophysiology 36 32 10% 9%

Neurovascular 81 81 1% (2%)

Cardiac Surgery 47 45 2% 2%

Cardiac Rhythm Management 517 446 16% 13%

CARDIOVASCULAR 1,597 1,626 (2%) (4%)

Oncology 58 60 (2%) (4%)

Endoscopy 212 187 13% 9%

Urology 100 93 8% 6%

ENDOSURGERY 370 340 9% 6%

NEUROMODULATION 81 60 36% 34%

WORLDWIDE $2,048 $2,026 1% (1%)

Growth rates are based on actual, non-rounded amounts

BOSTON SCIENTIFIC CORPORATION

WORLDWIDE SALES

(Unaudited)

Nine Months Ended

September 30, Change

As

Reported Constant

Currency Currency

In millions 2007 2006 Basis Basis

DOMESTIC $3,697 $3,579 3% 3%

Europe 1,327 1,150 15% 7%

Asia Pacific 850 686 24% 24%

Inter-Continental 330 341 (3%) (6%)

INTERNATIONAL 2,507 2,177 15% 10%

WORLDWIDE $6,204 $5,756 8% 6%

Nine Months Ended

September 30, Change

As

Reported Constant

Currency Currency

In millions 2007 2006 Basis Basis

Interventional

Cardiology $2,332 $2,781 (16%) (17%)

Peripheral Interventions/

Vascular Surgery 468 506 (8%) (10%)

Electrophysiology 109 99 9% 8%

Neurovascular 260 243 7% 5%

Cardiac Surgery 144 83 72% 72%

Cardiac Rhythm Management 1,580 882 79% 76%

CARDIOVASCULAR 4,893 4,594 6% 5%

Oncology 173 166 4% 3%

Endoscopy 620 556 11% 9%

Urology 295 273 8% 7%

ENDOSURGERY 1,088 995 9% 7%

NEUROMODULATION 223 167 34% 32%

WORLDWIDE $6,204 $5,756 8% 6%

Growth rates are based on actual, non-rounded amounts

BOSTON SCIENTIFIC CORPORATION

NON-GAAP CONSTANT CURRENCY NET SALES RECONCILIATIONS

THREE MONTHS ENDED SEPTEMBER 30, 2007

(Unaudited)

Q3 2007 Net Sales as compared to Q3 2006

Change

As Reported Constant Estimated

Currency Currency Impact of

In millions Basis Basis Foreign Currency

DOMESTIC $(66) $(66)

Europe 18 (12) $30

Asia Pacific 72 69 3

Inter-Continental (2) (8) 6

INTERNATIONAL 88 49 39

WORLDWIDE $22 $(17) $39

Q3 2007 Net Sales as compared to Q3 2006

Change

As Reported Constant Estimated

Currency Currency Impact of

In millions Basis Basis Foreign Currency

Interventional

Cardiology $(106) $(116) $10

Peripheral Interventions/

Vascular Surgery - (5) 5

Electrophysiology 4 3 1

Neurovascular - (1) 1

Cardiac Surgery 2 1 1

Cardiac Rhythm Management 71 58 13

CARDIOVASCULAR (29) (60) 31

Oncology (2) (2) -

Endoscopy 25 18 7

Urology 7 6 1

ENDOSURGERY 30 22 8

NEUROMODULATION 21 21 -

WORLDWIDE $22 $(17) $39

NOTE - An explanation of the ways in which Boston Scientific management uses these non-GAAP measures to evaluate its business, the substance behind Boston Scientific management's decision to use these non-GAAP measures, the material limitations associated with the use of these non-GAAP measures, the manner in which Boston Scientific management compensates for those limitations, and the substantive reasons why Boston Scientific management believes that these non-GAAP measures provide useful information to investors is included in the exhibit labeled "Use of Non-GAAP Financial Measures."

BOSTON SCIENTIFIC CORPORATION

NON-GAAP CONSTANT CURRENCY NET SALES RECONCILIATIONS

NINE MONTHS ENDED SEPTEMBER 30, 2007

(Unaudited)

Q3 2007 Net Sales as compared to Q3 2006

Change

As Reported Constant Estimated

Currency Currency Impact of

In millions Basis Basis Foreign Currency

DOMESTIC $118 $118

Europe 177 81 $96

Asia Pacific 164 166 (2)

Inter-Continental (11) (21) 10

INTERNATIONAL 330 226 104

WORLDWIDE $448 $344 $104

Q3 2007 Net Sales as compared to Q3 2006

Change

As Reported Constant Estimated

Currency Currency Impact of

In millions Basis Basis Foreign Currency

Interventional

Cardiology $(449) $(483) $34

Peripheral Interventions/

Vascular Surgery (38) (49) 11

Electrophysiology 10 9 1

Neurovascular 17 11 6

Cardiac Surgery 61 61 -

Cardiac Rhythm Management 698 667 31

CARDIOVASCULAR 299 216 83

Oncology 7 4 3

Endoscopy 64 50 14

Urology 22 20 2

ENDOSURGERY 93 74 19

NEUROMODULATION 56 54 2

WORLDWIDE $448 $344 $104

NOTE - An explanation of the ways in which Boston Scientific management uses these non-GAAP measures to evaluate its business, the substance behind Boston Scientific management's decision to use these non-GAAP measures, the material limitations associated with the use of these non-GAAP measures, the manner in which Boston Scientific management compensates for those limitations, and the substantive reasons why Boston Scientific management believes that these non-GAAP measures provide useful information to investors is included in the exhibit labeled "Use of Non-GAAP Financial Measures."

BOSTON SCIENTIFIC CORPORATION

ESTIMATED Q4 2007 NON-GAAP NET INCOME (LOSS) PER SHARE RECONCILIATION

(Unaudited)

Q4 2007 Estimate Q4 2007 Estimate

(Low) (High)

GAAP results (0.09) (0.02)

Estimated amortization expense 0.08 0.08

Estimated integration costs 0.01 0.01

Estimated restructuring and

restructuring-related expense 0.14 0.12

Adjusted results $0.14 $0.19

An explanation of the ways in which Boston Scientific management uses these non-GAAP measures to evaluate its business, the substance behind Boston Scientific management's decision to use these non-GAAP measures, the material limitations associated with the use of these non-GAAP measures, the manner in which Boston Scientific management compensates for those limitations, and the substantive reasons why Boston Scientific management believes that these non- GAAP measures provide useful information to investors is included in the exhibit labeled "Use of Non-GAAP Financial Measures."

Use of Non-GAAP Financial Measures

To supplement Boston Scientific's consolidated condensed financial statements presented on a GAAP basis; the Company discloses certain non-GAAP measures that exclude certain charges, including non-GAAP net income, non-GAAP net income per diluted share, and regional and divisional revenue growth rates that exclude the impact of foreign exchange. These non-GAAP measures are not in accordance with, or an alternative for, generally accepted accounting principles in the United States.

The GAAP measure most comparable to non-GAAP net income is GAAP net income and the GAAP measure most comparable to non-GAAP net income per diluted share is GAAP net income per diluted share. Reconciliations of each of these non-GAAP financon for the third quarter of 2007 as compared to $188 million for the third quarter of 2006. Worldwide sales of coronary stent systems for the third quarter of 2007 were $507 million as compared to $607 million for the third quarter of 2006. U.S. sales of coronary stent systems for the third quarter of 2007 were $268 million as compared to $397 million for the third quarter of 2006. International sales of coronary stent systems were $239 million for the third quarter of 2007 as compared to $210 million for the third quarter of 2006.

Worldwide sales of the Company's CRM group for the third quarter of 2007 were $517 million, which included $372 million of ICD sales, as compared to worldwide CRM sales of $446 million for the third quarter of 2006, which included $315 million of ICD sales. U.S. CRM sales for the third quarter of 2007 were $343 million, which included $261 million of ICD sales, as compared to U.S. CRM sales of $296 million for the third quarter of 2006, which included $221 million of ICD sales. International CRM sales for the third quarter of 2007 were $174 million, which included $111 million of ICD sales, as compared to International CRM sales of $150 million for the third quarter of 2006, which included $94 million of ICD sales.

Reported net loss for the third quarter of 2007 was $272 million, or $0.18 per share. Reported results for the third quarter of 2007 included acquisition- and divestiture-related charges (after-tax) of $435 million, or $0.29 per share, which included a previously disclosed and expected loss of approximately $352 million, primarily associated with the impairment of goodwill in connection with the anticipated sale of our auditory and drug pump businesses and $75 million of in-process research and development related to the acquisition of Remon Medical Technologies, Inc. Adjusted net income for the quarter, excluding acquisition- and divestiture-related charges and amortization expense, was $299 million, or $0.20 per sial measures to the corresponding GAAP measure are included in the accompanying schedules.

To calculate regional and divisional revenue growth rates that exclude the impact of foreign exchange, the Company converts actual current-period net sales from local currency to U.S. dollars using constant foreign exchange rates. The GAAP measure most comparable to this non-GAAP measure is growth rate percentages based on GAAP revenue. A reconciliation of this non-GAAP financial measure to the corresponding GAAP measure is included in the accompanying schedules.

Use and Economic Substance of Non-GAAP Financial Measures Used by Boston Scientific

Management uses these supplemental non-GAAP measures to evaluate performance period over period, to analyze the underlying trends in the Company's business, to assess its performance relative to its competitors, and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP measures to further its understanding of the performance of the Company's operating segments. The adjustments excluded from the Company's non-GAAP measures are consistent with those excluded from its reportable segments' measure of profit or loss. These adjustments are excluded from the segment measures that are reported to the Company's chief operating decision maker and are used to make operating decisions and assess performance.

The following is an explanation of each of the adjustments that management excluded as part of its non-GAAP measures for the three and nine month periods ending September 30, 2007 and September 30, 2006 and for the forecasted three month period ending December 31, 2007, as well as reasons for excluding each of these individual items:

- Acquisition and divestiture-related charges - For the three and nine

months ending September 30, 2007 and September 30, 2006, these

adjustments primarily consisted of: purchased research and development;

a loss on assets held for sale related to the Company's anticipated

divestiture of certain components of its Neuromodulation business;

integration costs associated with the Company's acquisition of Guidant;

the fair value adjustment related to the sharing of proceeds feature of

the Abbott stock purchase; the step-up value of acquired Guidant

inventory sold during the period; the AAA program cancellation net

credit, which consisted of a credit to purchased research and

development, facility and severance costs associated with the program

termination and amortization expense associated with an impairment

charge on the remaining intangible assets; a CRM technology offering

charge to make available the Latitude(R) Patient Management System; and

a charitable contribution. Purchased research and development is a

highly variable charge based on valuation assumptions. Management

removes the impact of purchased research and development from the

Company's operating results to assist in assessing the Company's

operating performance and cash generated from operations. The loss on

assets held for sale represents a one-time charge associated with our

intent to sell certain components of our Neuromodulation business, and

is not indicative of future operating performance and is not used by

management to assess operating performance. The integration costs

associated with the Company's acquisition of Guidant do not reflect

expected on-going future operating expenses. The fair value adjustment

related to the sharing of proceeds feature of the Abbott stock purchase

is a non-cash adjustment and is not indicative of the Company's on-

going operations. The step-up value of acquired inventory is a cost

directly attributable to the Guidant acquisition and is not indicative

of the Company's on-going operations, or on-going cost of products

sold. The facility and severance costs related to the AAA program

cancellation do not reflect expected future operating expenses; in

addition, the amortization charge associated with the impairment of the

related intangible assets is a non-cash charge and is not reflective of

future operating performance. The CRM technology offering charge

represents a one-time cost associated with making this technology

available to existing patients and the cost is not indicative of future

expenses associated with the technology. The charitable contribution

does not reflect expected future operating expenses. Accordingly,

management excluded these charges for purposes of calculating these

non-GAAP measures to facilitate an evaluation of the Company's current

operating performance and a comparison to the Company's past operating

performance.

- Amortization expense - Amortization expense is a non-cash charge and

does not impact the Company's liquidity or compliance with the

covenants included in its debt agreements. Following the Company's

acquisition of Guidant, and the related increase in the Company's debt,

management has heightened its focus on cash generation and debt pay

down. Management removes the impact of amortization from the Company's

operating performance to assist in assessing the Company's cash

generated from operations. Management believes this is a critical

metric for the Company in measuring the Company's ability to generate

cash and pay down debt. Therefore, amortization expense is excluded

from management's assessment of operating performance and is also

excluded from the measures management uses to set employee

compensation. Accordingly, management believes this may be useful

information to users of its financial statements and therefore has

excluded these charges for purposes of calculating these non-GAAP

measures to facilitate an evaluation of the Company's current operating

performance, particularly in terms of liquidity.

- Foreign exchange on net sales - The impact of foreign exchange is

highly variable and difficult to predict. Accordingly, management

excludes the impact of foreign exchange for purposes of reviewing

regional and divisional revenue growth rates to facilitate an

evaluation of the Company's current operating performance and

comparison to the Company's past operating performance.

- Restructuring and restructuring-related expenses - These expenses

represent employee-related costs, asset write-downs and other costs

associated with the Company's restructuring initiatives. These costs do

not reflect expected on-going future operating expenses and Boston

Scientific management will exclude them in assessing its operating

performance, and will exclude them from its operating segments'

measures of profit and loss used for making operating decisions and

assessing performance.

Material Limitations Associated with the Use of Non-GAAP Financial Measures

Non-GAAP net income, non-GAAP net income per diluted share, and regional and divisional revenue growth rates that exclude the impact of foreign exchange may have limitations as analytical tools, and these non-GAAP measures should not be considered in isolation or as a replacement for GAAP financial measures. Some of the limitations associated with the use of these non-GAAP financial measures are:

- Items such as purchased research and development, the step-up value of

acquired Guidant inventory sold during the period, the CRM technology

offering charge, the loss on assets held for sale, and the fair value

adjustment related to the sharing of proceeds feature of the Abbott

stock purchase reflect economic costs to the Company and are not

reflected in non-GAAP net income and non-GAAP net income per diluted

share.

- Items such as Guidant integration costs, facility and severance costs,

the charitable contribution, and restructuring and restructuring-

related expenses that are excluded from non-GAAP net income and non-

GAAP net income per diluted share can have a material impact on cash

flows and GAAP net income and net income per diluted share.

- Items such as amortization of purchased intangible assets, though not

directly affecting Boston Scientific's cash flow position, represent a

reduction in value of intangible assets over time. The expense

associated with this reduction in value is not included in Boston

Scientific's non-GAAP net income or non-GAAP net income per diluted

share and therefore these measures do not reflect the full economic

effect of the reduction in value of those intangible assets.

- Revenue growth rates stated on a constant currency basis, by their

nature, exclude the impact of foreign exchange, which may have a

material impact on GAAP net sales.

- Other companies may calculate non-GAAP net income, non-GAAP net income

per diluted share, or regional and divisional revenue growth rates that

exclude the impact of foreign exchange differently than Boston

Scientific does, limiting the usefulness of those measures for

comparative purposes.

Compensation for Limitations Associated with Use of Non-GAAP Financial Measures

Boston Scientific compensates for the limitations on its non-GAAP financial measures by relying upon its GAAP results to gain a complete picture of the Company's performance. The non-GAAP numbers focus instead upon the core business of the Company, which is only a subset, albeit a critical one, of the Company's performance.

The Company provides detailed reconciliations of each non-GAAP financial measure to its most directly comparable GAAP measure in the accompanying schedules, and Boston Scientific encourages investors to review these reconciliations.

Usefulness of Non-GAAP Financial Measures to Investors

The Company believes that presenting non-GAAP net income, non-GAAP net income per share, and regional and divisional revenue growth rates that exclude the impact of foreign exchange in addition to the related GAAP measures provides investors greater transparency to the information used by Boston Scientific management for its financial and operational decision-making and allows investors to see Boston Scientific's results "through the eyes" of management. The Company further believes that providing this information better enables Boston Scientific's investors to understand the Company's operating performance and to evaluate the methodology used by management to evaluate and measure such performance. Disclosure of these non-GAAP financial measures may also facilitate comparisons of Boston Scientific's operating performance with the performance of other companies that supplement their GAAP results with non-GAAP financial measures.

hare. Reported net income for the third quarter of 2006 was $76 million, or $0.05 per share. Reported results for the third quarter of 2006 included acquisition-related charges (after-tax) of $77 million, or $0.05 per share. Adjusted net income for the third quarter of 2006, excluding acquisition-related charges and amortization expense, was $271 million, or $0.18 per share.

"The quarter represented something of a turn for us, with a number of positive developments, including our attaining the number one position in worldwide drug-eluting stent sales, significant market share growth in drug-eluting stents, strong year-over-year cardiac rhythm management growth and continued solid growth in Endosurgery," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "Going forward, the restructuring initiatives we announced earlier this week will help us better focus on our core businesses and priorities, to strengthen the Company for the future and should lead to improved, long-term, profitable sales growth."

Guidance for Fourth Quarter 2007

The Company estimates net sales for the fourth quarter of 2007 between $2.05 billion and $2.15 billion. Adjusted earnings -- excluding charges related to acquisitions, divestitures and restructuring, and amortization expense -- are estimated to be in a range of $0.14 and $0.19 per share. The Company estimates a net loss on a GAAP basis between $0.09 and $0.02 per share. GAAP guidance excludes any potential gains or losses related to disposition of previously announced business divestitures.

Boston Scientific officials will be discussing these results with analysts on a conference call at 8:00 a.m. (ET) Friday, October 19, 2007. The Company will webcast the call to all interested parties through its website: http://www.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for one year on the Boston Scientific website.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our financial performance and flexibility, our restructuring plan, our growth strategy, market recovery and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

Use of non-GAAP Financial Information

To supplement Boston Scientific's consolidated condensed financial statements presented on a GAAP basis, the Company discloses certain non-GAAP measures that exclude certain charges, including non-GAAP net income/loss and non-GAAP net income/loss per diluted share. These non-GAAP measures are not in accordance with, or an alternative for, generally accepted accounting principles in the United States. A reconciliation of the non-GAAP financial measures to the corresponding GAAP measures is included in the tables below. In addition, an explanation of the ways in which Boston Scientific management uses these non-GAAP measures to evaluate its business, the substance behind Boston Scientific management's decision to use these non-GAAP measures, the material limitations associated with the use of these non-GAAP measures, the manner in which Boston Scientific management compensates for those limitations, and the substantive reasons why Boston Scientific management believes that these non-GAAP measures provide useful information to investors is included under "Use of Non-GAAP Financial Measures" after the tables below. This additional non-GAAP financial information is not meant to be considered in isolation or as a substitute for financial information prepared in accordance with GAAP.

CONTACT: Paul Donovan Dan Brennan

508-650-8541 (office) 508-650-8538 (office)

508-667-5165 (mobile) 617-459-2703 (mobile)

Media Relations Investor Relations

Boston Scientific Corporation Boston Scientific Corporation

BOSTON SCIENTIFIC CORPORATION

CONDENSED GAAP RESULTS OF OPERATIONS

(Unaudited)

Three Months Ended

September 30,

In millions, except per share data 2007 2006

Net sales $2,048 $2,026

Cost of products sold 575 630

Gross profit 1,473 1,396

Operating expenses

Selling, general and administrative

expenses 719 719

Research and development expenses 271 272

Royalty expense 48 57

Amortization expense 155 153

Purchased research and development 75

Loss on assets held for sale 352

1,620 1,201

Operating (loss) income (147) 195

Other income (expense):

Interest expense (147) (143)

Other, net 35 (1)

(Loss) income before income taxes (259) 51

Income taxes 13 (25)

Net (loss) income $(272) $76

Net (loss) income per common share -

assuming dilution $(0.18) $0.05

Weighted average shares outstanding -

assuming dilution 1,489.8 1,486.7

BOSTON SCIENTIFIC CORPORATION

NON-GAAP NET INCOME (LOSS) AND NET INCOME (LOSS)

PER COMMON SHARE RECONCILIATIONS

(Unaudited)

NOTE - An explanation of the ways in which Boston Scientific management uses these non-GAAP measures to evaluate its business, the substance behind Boston Scientific management's decision to use these non-GAAP measures, the material limitations associated with the use of these non-GAAP measures, the manner in which Boston Scientific management compensates for those limitations, and the substantive reasons why Boston Scientific management believes that these non-GAAP measures provide useful information to investors is included in the exhibit labeled "Use of Non-GAAP Financial Measures."

Three Months Ended Three Months Ended

September 30, September 30,

2007 2006

Impact Impact

Net per per

income diluted Net diluted

(loss) share income share

In millions, except per share data

GAAP results $(272) $(0.18) $76 $0.05

Non-GAAP adjustments:

Acquisition and divestiture

related charges 435 0.29 77 0.05

Amortization expense 136 0.09 (1) 118 0.08

Adjusted results $299 $0.20 (1) $271 0.18

(1) Calculated by assuming stock-based dilution of 12.5 million shares

Three Months Ended

September 30,

2007 2006

Acquisition and divestiture related

charges:

Loss on assets held for sale $352

Purchased research and development 75

Integration costs (a) 10 $9

Step-up value of inventory sold (b) 94

Fair-value adjustment for the sharing

of proceeds feature of the Abbott

Laboratories stock purchase (c) 13

CRM technology offering charge (b) 31

437 147

Income tax benefit (d) (2) (70)

Acquisition and divestiture related

charges, net of tax $435 $77

Amortization expense:

Amortization expense $155 $153

Income tax benefit (d) (19) (35)

Amortization expense, net of tax $136 $118

(a) Recorded $8 million in 2007 to selling, general and administrative

expenses, $2 million to cost of products sold; recorded $7 million in

2006 to selling, general and administrative expenses, and $2 million

to research and development expenses.

(b) Recorded to cost of products sold.

(c) Recorded to other, net.

(d) Amounts are tax effected at the Company's anticipated effective tax

rate, unless the amount is a significant unusual or infrequently

occurring item in accordance with FASB Interpretation No. 18,

"Accounting for Income Taxes in Interim Periods".

BOSTON SCIENTIFIC CORPORATION

CONDENSED GAAP RESULTS OF OPERATIONS

(Unaudited)

Nine Months Ended

September 30,

In millions, except per share data 2007 2006

Net sales $6,204 $5,756

Cost of products sold 1,706 1,681

Gross profit 4,498 4,075

Operating expenses

Selling, general and administrative

expenses 2,205 1,917

Research and development expenses 835 741

Royalty expense 151 177

Amortization expense 467 356

Purchased research and development 72 4,117

Loss on assets held for sale 352

4,082 7,308

Operating income (loss) 416 (3,233)

Other income (expense):

Interest expense (433) (291)

Other, net
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The birth of biotech: San Francisco, Boston, Geneva or Chicago?
2. Wicab to present BrainPort at Boston conference
3. Boston equity firm becomes majority owner of Cedarburg-based Mortgagebot
4. Boston entrepreneur to enliven Milwaukee angel group
5. UW-Madisons Beebe wins scientific award
6. Researchers say scientific reporting needs more perspective, less hype
7. Wisconsin stands at the center of scientific efforts to avert flu epidemics
8. Growth prompts new location for scientific instrument manufacturer
9. UW stem cell guru outlines scientific and political future
10. Wisconsin biotech sector featured in scientific magazine
11. Scientific Protein Laboratories Acquired by New York firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2016)... ... May 18, 2016 , ... Ryan Benton was diagnosed ... expectancy in the late teens to early twenties. DMD is a relatively common progressive ... the age of 22, Benton’s condition was critical. He met with the founder of ...
(Date:5/17/2016)... Texas (PRWEB) , ... May 17, 2016 , ... ... for use in animal waste reduction applications, announced today it will be showcasing ... Moines, Iowa. , ManureMagic™ was featured in the Wall Street Journal last year ...
(Date:5/17/2016)... ... 17, 2016 , ... PATH and Laerdal Global Health announced ... a feeding cup to market based on a reference design co-developed by PATH, ... Children’s Hospital, thereby ensuring an innovative feeding option for the 7.6 million preterm ...
(Date:5/17/2016)... 2016 Strekin AG, a ... Basel, Switzerland announced today the in-licensing ... mitogen-activated protein kinase.      (Logo: ... build the necessary research foundation for the clinical ... Kinases play fundamental roles. Pamapimod has a well-established ...
Breaking Biology Technology:
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
Breaking Biology News(10 mins):